initi buy new kid ney
diagnost block long growth runway
initi coverag buy rate pt strongli
posit leader transplant diagnost market
two commerci test serv unmet need non-invas
detect heart kidney post-transpl reject believ market
underappreci runway continu allosur kidney growth
forecast revenue compound-annual-growth-rate thru higher specialti dx lab peer
jefferi joint book-run manag equiti offer
allosur momentum build long runway ahead test less invas
 accur legaci method alreadi broad reimburs new
allosur test launch kidney transplant surveil strong first-mov
advantag us measur initi launch one best
seen top us center perform transplant alreadi
use yet adopt remain earli inning penetr time think
allosur match allomap success heart transplant share -- translat
pathway ep power forecast rev
rise allosur adopt assum captur new kidney transplant similar
allomap complianc protocol post well penetr
exist preval market minim spend need ramp allosur
sale channel allomap model highli scalabl forecast ebit margin
ep
uniqu model diagnost uniqu busi model diagnost
one view similar colorect cancer screeningin term direct
commun captiv base transplant patient requir activ surveil
 repeat test post-transpl monitor reject creat recur
revenu oppt test patient multipl time multi-year period like
strong complianc engin drive high adher test protocol
unlik small cap dx co alreadi ebitda cash flow posit
premium valuat justifi materi outperform last year
back strong initi allosur roll-out see upsid ahead launch
play given superior top-lin growth profil compound-annual-growth-rate thru vs
average specialti dx lab peer believ valuat premium justifi
pt impli ev/rev vs peer
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
strongli posit leader transplant dx
rev allosur test
penetr us kidney transplant market
valu futur pipelin test
price target base rev
ebitda discount back
two commerci test address unmet need
non-invas detect heart kidney transplant
reject importantli test reimburs
view cdna busi post-transpl space
uniqu recur revenu model repeat test
similar mani way
scalabl model consider oper leverag
forecast ebit margin ep
initi read-out k-oar shore longitudin
new pipelin launch alloseq cfdna alloseq
bmt solid organ allosur
layer data/oth offer
similar allomap allosur test
penetr rev
success longitudin studi k-oar shore
drive faster penetr util
compliance/adher allosur protocol
price target base rev discount
back
higher-than-expect oper expens support
allosur commerci roll-out
increas competit loss key high-volum transplant
dilut financ fund pipelin acquisit
price target ev rev discount
median specialti diagnost lab
page
pleas see import disclosur inform page report
initi buy pt
page
pleas see import disclosur inform page report
portfolio manag summari thesi nutshel
introduct
page
pleas see import disclosur inform page report
thesi nutshel
leader attract market unmet need establish brand transplant channel unmet need
transplant diagnost heart kidney high-cost patient current surveil method huge limit either
invas biopsi inadequ serum creatinin well-known establish leader serv pre- post-transpl market
w/ mover advantag pioneer use measur dd-cfdna blood detect activ reject kidney
transplant launch cdna new allosur test serv us market opportun
uniqu captiv model repeat test post-transpl diagnost one dx market know recur
revenu dynam repeat test transplant patient long period time similar colorect cancer screen
heart transplant patient recommend test thereaft
kidney transplant patient recommend test thereaft
complianc protocol adher patient requir activ monitor regular blood draw ensur bodi
reject organ accur titrat immunosuppress drug dosag
heart center us half market procedur volum center activ allomap user
kidney center market procedur volum us
minim reimburs risk allomap fda approv cover medicar us test market volum along
sever larg commerci payor allosur also cover medicar market reimburs risk
bottom line like fundament stori huge unmet need better differenti solut big
momentum allosur launch build reimburs risk cdna recent equiti rais significantli strengthen
balanc sheet remov fund overhang execut stori
compel valuat trade ev/rev discount specialti dx lab peer median despit
superior growth outlook compound-annual-growth-rate thru vs peer see scope rev drive
ebitda ep pt assum revenu ebitda discount back
page
pleas see import disclosur inform page report
intro
page
pleas see import disclosur inform page report
found ipo headquart brisban ca
commerci stage global leader transplant molecular diagnost
full suit products/servic pre- post-transpl care
post-transpl revenu
allomap rev flagship test launch
fda-clear first non-invas test use blood sampl
monitor acut cellular reject heart transplant recipi
de-facto gold standard test use us heart transplant center
penetr new patient
advantag gene express indic acut cellular reject well
damag visibl tissu biopsi enabl clinician avoid
allosur rev launch medicar cover
first non-invas blood test acut kidney transplant reject
use measur dd-cfdna blood donor kidney
legaci method either ineffect low sensit serum creatinin
invas biopsi surveil tool caus delay injuri detect
current penetr annual us kidney transplant
expand long growth
allomap us
pre-transpl revenu
product facilit better match donor recipi
enter pre-transpl dx market
broad-rang hla human leukocyt antigen match product
launch allosur kidney transplant
reject ad us market
product three product roll
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
good market
captiv recur revenu dynam post-transpl market one diagnost market know recur
revenu dynam patient need frequent repeat test multi-yr period
diagnost one-tim test howev heart kidney transplant patient need test post monitor reject
direct commun interact captiv patient popul multi-year period
complianc engin in-plac remind patient get blood draw patient care manag today
model similar colorect cancer screen view focu retest patient everi year recommend screen interv
heart transplant center us center total procedur volum
kidney center us total procedur volum
bottom line market requir rel small commerci team unlik mani diagnost often physician call point
unmet need transplant diagnost
transplant patient requir life-long immunosuppress drug requir activ surveil care failur higher healthi patient
current standard heart biopsi invas error-pron caus lt risk trauma organ surveil diminish post
current standard kidney serum creatinin assay indic diminish kidney function poor sensitivity/specif often detect
injury/reject irrevers loss renal function occur make hard adjust immunosuppress dosag abnorm level requir
invas tissu biopsi confirm
page
pleas see import disclosur inform page report
allomap heart allosur kidney annual transplant us exist popul transplant us transplant center center volum recommend test year testsrecommend test yr testsmarket size billionmedicar
usual one king top hierarchi
market
market
strict king top term protocol adher
focu surviv rate good enough
less-concern whether patient go diabet
post over-immunuosuppress
focu long-term outcom want patient
keep come back time
hardest adopt convert allosur
easiest user convert allosur
moat barrier entri center adopt cdna routin test
schedul protocol workflow sticki hard chang
page
pleas see import disclosur inform page report
blood test measur level donor-deriv cell free dna
dd-cfdna blood indic kidney injuri
new applic cfdna similar pre-nat nipt
dd-cfdna provid quantifi direct measur allograft damag
benefit faster quantit result compar legaci method highli
accur differenti reject vs non-reject non-invas procedur
earlier detect better lt care health outcom reduc risk
downstream advers effect immunosuppress drug reduc unnecessari
mover advantag alreadi deep exist relationship
transplant center allomap use us heart transplant center
analyt valid journal molecular diagnost octob
definit refer popul journal appli lab medicin nov
clinic validity/util journal amer societi nephrolog juli
dart studi prospect multi-cent prove dd-cfdna measur
allosur assay highli correl activ reject serum
creatinin level differenti reject non-reject
reimburs statu establish medicar price coverag
kidney transplant patient us
defens strong broad ip protect relat cf-dna transplant
via acquisit immumetrix
page
pleas see import disclosur inform page report
allosur launch strong gate
measur initi first-year allosur launch among best new diagnost test launch view
patient result impress test volum growth q/q test penetr
order center kidney center alreadi order us center launch target current use allosur
longitudin mileston enrol k-oar long-term outcom studi strong start enrol center
surveil patient alreadi patient koar non-koar manag pre-defin transplant center protocol
initi enrol patient see similar progress patient target vs initi goal
physician alreadi place stand order least provid high visibl futur test demand
bottom line encourag initi launch uptak progress posit gold standard surveil test multipl clinic
studies/publ provid solid foundat build next sever year
page
pleas see import disclosur inform page report
result uniqu patient test order center -order center qtr new stand order patient -current surveil
current work addit studi koar kidney allograft outcom allosur registri intend develop
data clinic util allosur surveil kidney transplant patient
palmetto posit coverag decis conting upon data develop commenc studi jan
clinic outcom studi enrol patient initi target across transplant center scope
recent upsiz given high particip interest studi
studi observ patient outcom post-transpl total number renal biopsi perform rel control
primari end point safeti amount kidney tissu scar efficaci number renal biopsi perform first year
current enrol statu center initi registri studi site patient enrol
add visibl revenu volum expect allosur test yr studi period translat rev
page
pleas see import disclosur inform page report
allosur size market opportun
note assum medicar reimburs rate compliance/adher test protocol
allosur us kidney transplant market base annual address popul new kidney transplant patient
exist patient preval market
overal annual test opportun test new transplant patient tests/yr subsequ period post cohort
potenti upsid catalyst ou expans addit coverag decis commerci payor
allosur revenu forecast assumpt adher similar allomap grow penetr today rise
 increment privat payor coverag conserv assum allosur captur new kidney patient similar allomap
today preval market
allomap captur us market dollar perspect share allosur market annual revenu
page
pleas see import disclosur inform page report
allosur market opportun build number kidney transplant annual us frequenc kidney frequenc test address assumpt volum price realiz asp revenu transplant market opportun
allosur theoret oppti new transplant patient life span
given recur natur model attempt sketch
theoret waterfal allosur year period expect lifespan
captur new kidney transplant patient similar allomap
lifetim adher rate protocol test per new patient
tests/pati subsequ year
reimburs medicar rate realiz asp/test
conclus estimate new cohort could gener cumul
revenu year span averag
page
pleas see import disclosur inform page report
